INTERSECT ENT, INC. Inactive Instrument
Intersect ENT, Inc.
Equities
XENT
US46071F1030
Medical Equipment, Supplies & Distribution
Presenter SpeechK. Gong (Analysts)Okay. I'd like to welcome everyone to the afternoon sessions...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Intersect ENT, Inc. is a global ear, nose, and throat (ENT) medical technology company. The Company's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. It also offers ENT products, such as VenSure and CUBE.
| 1st Jan change | Capi. | |
|---|---|---|
| -4.84% | 182B | |
| +0.56% | 110B | |
| -3.35% | 68.11B | |
| +2.39% | 50.53B | |
| +9.36% | 44.8B | |
| +2.98% | 40.7B | |
| +24.51% | 32.3B | |
| +3.43% | 26.53B | |
| +13.95% | 25.02B |
